Loading
Genetic and Kidney Cyst Diseases · Journal article
Hereditas · August 24, 2026
Raises a question worth testing. It does not answer one.
This study provides computational and molecular evidence that KIF11 is overexpressed in colorectal cancer and involved in cell-cycle control, and that nitidine chloride computationally docks to KIF11, but does not demonstrate that NC actually suppresses CRC growth in vivo or that KIF11 inhibition translates to clinical benefit. The work is mechanistic hypothesis generation requiring independent translational validation.
Multi-method mechanistic discovery study including meta-analysis of public datasets and in vitro cell-based experiments. Public CRC datasets (unspecified number of cohorts); 416 CRC clinical specimens from in-house collection (setting, eligibility criteria not detailed); multiple CRC cell lines; unspecified number of xenograft models. Intervention: Nitidine chloride treatment (dose, duration, concentration not specified); KIF11 knockdown by CRISPR and lentiviral silencing. Compared with: Control cell lines; wild-type cells; untreated cells (explicit comparator groups and their definitions not fully detailed).
Molecular docking predicted strong NC–KIF11 interaction (−9.0 kcal/mol) Meta-analysis across public datasets showed KIF11 mRNA overexpression in CRC (SMD = 1.33; AUC = 0.87) Clinical immunohistochemistry on 416 specimens demonstrated KIF11 protein-level elevation (AUC = 0.99) correlated with larger tumor size and deeper invasion
No direct measurement of nitidine chloride's antitumor effect in vivo; authors acknowledge absence of comprehensive xenograft and in vivo pharmacodynamic validation Clinical specimens are retrospective and correlative; no prospective efficacy or toxicity data in any organism
This study does not yet support clinical use of nitidine chloride or KIF11-directed therapy in CRC. Clinicians should recognize this as hypothesis-generating preclinical work requiring independent animal efficacy studies and eventual clinical trial validation before considering any therapeutic application.
This is a mechanistic discovery study combining computational prediction, molecular profiling, and cell-based experiments that propose KIF11 as a target and NC as a candidate agent, but lacks clinical efficacy data, adequate in vivo validation, or direct evidence of NC's antitumor effect in animal models.
As stated by the source record.
Quoted from the source exactly as published.
This study does not yet support clinical use of nitidine chloride or KIF11-directed therapy in CRC. Clinicians should recognize this as hypothesis-generating preclinical work requiring independent animal efficacy studies and eventual clinical trial validation before considering any therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Colorectal cancer (CRC) remains a leading cause of cancer mortality with few effective targeted therapies. Kinesin family member 11 (KIF11), a motor protein essential for mitotic spindle assembly, is frequently overexpressed in multiple cancers. We hypothesized that nitidine chloride (NC), a natural benzophenanthridine alkaloid with documented anti-tumor activity, might suppress CRC by targeting KIF11.Molecular docking predicted a strong interaction between NC and KIF11 (− 9.0 kcal/mol). RNA sequencing, quantitative RT-PCR, and immunohistochemistry confirmed that NC treatment markedly downregulated KIF11 expression. Meta-analysis across public datasets showed consistent KIF11 mRNA overexpression in CRC (standardized mean difference [SMD] = 1.33; AUC = 0.87), while in-house immunohistochemistry on 416 clinical specimens demonstrated even stronger protein-level elevation (AUC = 0.99) that correlated with larger tumor size and deeper invasion. Single-cell RNA sequencing and spatial transcriptomics further revealed that KIF11 is preferentially expressed in proliferative malignant epithelial cells. Through CRISPR-based knockout screening and lentiviral silencing, KIF11 depletion impaired the growth or viability of the examined CRC cell models. Public ChIP-seq data suggested RAD21 occupancy near the KIF11 regulatory region, whereas reciprocal co-immunoprecipitation supported an association between the RAD21 and KIF11 proteins. Among genes co-expressed with KIF11,a pronounced enrichment was observed in pathways governing cell-cycle progression. Following KIF11 knockdown, transcriptomic profiling showed reduced expression across cell-cycle, DNA-replication, and chromatin-cohesion programs, alongside a reciprocal increase in amino-acid metabolism and stress-response genes. At the functional level, KIF11 depletion suppressed cell proliferation and induced G2/M-phase arrest. Taken together, these in vitro and limited xenograft data indicate that NC restrains CRC growth chiefly through the RAD21–KIF11 axis; KIF11 represents a promising preclinical target, though comprehensive systematic in vivo pharmacodynamic and translational animal validation remains absent in the current study and requires further independent investigation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.